New R&D and cGMP Manufacturing Campus will located in Changzhou

WuXi PharmaTech Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou

SHANGHAI, May 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development (R&D) services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd., has begun construction of a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai.  The new construction aims to meet the rapidly growing demand for WuXi's manufacturing services, which have quadrupled their revenues in the past four years.

The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities.  Facilities constructed in phase 1 will double the company's current manufacturing capacity and be operational by the fourth quarter of 2015.  Upon completion of the entire project, the site will triple current capacity and can have more than 1,500 employees, including chemists, production staff, and supporting staff, to seamlessly move new chemical entities from early stage process development through preclinical and clinical deliveries to commercial production.

"This project marks an important milestone in STA's mission of building a fully integrated API development and manufacturing platform," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  "It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients."

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
+1 (201) 585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.

RELATED LINKS
http://www.wuxiapptec.co
m

呜呜呜，楼主翻译下啊，看不懂啊

谢谢xiaoxiao的关注！因为考虑到这是药研与注册论坛，关心本论坛的群员应该也会关心全球药研的动态和趋势，语言的学习和训练是必不可少的，所以就直接转发了。如xiaoxiao确实十分想知道文章的内容，可发邮件给我，我会专门准备译文给你了。如果觉得学习语言对于现在的药研或注册的工作有帮助，我个人还是建议自己尝试泛读理解一下。我的信箱：413701533@qq.com. Have a good day!